What is Semaglutide?

GLP-1 increases insulin secretion; increases glucose-dependent insulin synthesis and insulin secretion in vivo by pancreatic beta cells at elevated glucose levels. In addition to increasing insulin secretion and synthesis, GLP-1 inhibits Glc secretion, slows gastric emptying, reduces food intake, and promotes beta cell proliferation. Semaglutide lowers blood glucose through a mechanism by which it stimulates insulin secretion and decreases Glc secretion, both in a glucose-dependent manner. Therefore, when blood sugar is high, insulin secretion is stimulated and Glc secretion is inhibited. Also, the mechanism for lowering blood glucose is a slight delay in gastric emptying in the early postprandial period.

Cyanocobalamin

This vitamin also plays an important role in protein synthesis, nervous metabolism, DNA and RNA production, and fat and carbohydrate metabolism. CoA. These two methylation reactions are essential for cell growth and cell reproduction. Methionine, an exogenous sulfur amino acid, is a precursor to S-adenosylmethionine, a cofactor in single-carbon metabolism and a final methyl donor in the methylation of DNA, RNA, proteins, and phospholipids. When the body lacks cobalamin, methylmalonyl-CoA builds up, which is believed to lead to the neurological symptoms of vitamin B12 deficiency. Parenteral cyanocobalamin supplementation results in a rapid and complete improvement in megaloblastic anemia and gastrointestinal symptoms caused by vitamin B12 deficiency.

Purpose

Semaglutide Injection is a once-a-week dose that works by mimicking hormones that target areas of the brain involved in regulating appetite and food intake. This can help you eat less and lead to weight loss.
Our Semaglutide is combined with B12 for energy, sleep cycle regulation and a better patient experience,

Benefits

– Weight Loss
– May improve Blood Pressure
– May improve cholesterol
– Improves Blood Sugar

Semaglutide/B12 Injection HOMEKIT w/ TeleHealth Physicians Consultation

$399.00

Home Kit Includes:

1 month supply of Semaglutide/B12 Combination Injection
(Dosage varies from 0.25mg – 2.4mg and is dependent on the Month ordered)
Syringes
Alcohol Pads
Physician Consultation [online]

Procedure

Subcutaneous (Sub-q) Injection, self-administered in the fatty abdominal area or thigh.
Video tutorial provided after purchase.

Dosage and Frequency

Once a week
Taken on the same day each week, any time of day, with or without food.
SEE INGREDIENTS BELOW
(Detailed dosing schedule will be provided with Homekit)

Diet and Exercise

Healthy eating and activity are recommended.

Most Common Side Effect (Full list below)

Nausea
(Recommendations to limit Nausea: Eat bland, low-fat foods, like crackers, toast and rice. Eat foods that contain water, like soup and gelatin. Avoid laying down after eating. Eat slowly. Go outdoors for fresh air.)

Reference:

The effect of (L-)carnitine on weight loss in adults: a systematic review and meta-analysis of randomized controlled trials
Inositol and Body Mass

TeleHealth Consultation

A physician may contact you within 24 hours of purchase if additional information is needed.

IMPORTANT!

THIS PRODUCT FOLLOWS A TITRATION SCHEDULE. ALL PATIENTS MUST START WITH THE ‘MONTH 1’ DOSE. AFTER MONTH 1, THE DOSAGE PER INJECTION INCREASES GRADUALLY IN MONTHS 2, 3, AND 4. LASTLY, THE MAINTENANCE DOSE CAN BE ONGOING FOR UP TO 8 MONTHS DEPENDING ON YOUR GOALS

A MINIMUM BMI OF 27 OR GREATER IS REQUIRED TO ORDER THIS PRODUCT

Shipping

This product can be shipped 2-Day or Overnight and does not need to be refrigerated during shipping. As a precaution, please refrigerate once received and opened.

SHOP

Semaglutide

Semaglutide is a synthetic GLP-1 receptor agonist used to treat type 2 diabetes. It mimics incretin hormones, like GLP-1, to control blood sugar. Administered via injection (Ozempic) or oral tablets (Rybelsus), it improves glycemic control and reduces cardiovascular risks in diabetic patients. There's a boxed warning about potential thyroid tumors in rodents. GLP-1 receptor agonists, including semaglutide, are recommended as first-line treatments for diabetes patients with cardiovascular risks. Semaglutide, liraglutide, and dulaglutide show strong cardiovascular benefits. GLP-1 receptor agonists are effective in lowering blood sugar, especially semaglutide. They also benefit patients with heart failure or kidney disease. Semaglutide (Wegovy) is also indicated for obesity treatment. Clinical trials showed significant weight loss. Weight loss medications are recommended with lifestyle changes for obese patients. Individualized treatment is suggested based on medication characteristics and patient history.

Cyanocobalamin

Cyanocobalamin is a synthetic form of vitamin B12, part of the B-complex family. It's available as a prescription or

over-the-counter medication and is commonly used in supplements and fortified foods. Unlike its natural counterparts, it contains a cyanide group that stabilizes its structure. Hydroxocobalamin is a more active form of B12. Cyanocobalamin is made through bacterial fermentation, is stable, and comes in various forms including red powder or crystals. It's soluble in water and alcohol but not in other solvents. This vitamin is used in tablets, nasal sprays, and injections and was approved by the US FDA in 1942. It's widely used for treating B12 deficiency since the 1950s.

The lack of vitamin B12 may result from any of the following conditions:

Addisionian (pernicious) anemia - this condition causes autoantibody formation against parietal cells, which results in a lack of IF essential for the absorption of vitamin B12 from the intestine
Malabsorption — impaired absorption of vitamin B12
Gastrointestinal pathology, dysfunction, or surgery — these include atrophic gastritis, celiac disease, small bowel bacterial overgrowth, pancreatic insufficiency, Helicobacter pylori infection, gastric carcinoma, and total or partial gastrectomy
Diphyllobothrium latum and related species (the fish tapeworm) infestation — these parasites compete with vitamin B12 for intestinal absorption; this leads to malabsorption of the vitamin
Certain medications use — long-term metformin use and chronic acid-reducing drugs decrease the absorption of vitamin B12 from food particles
Malignancy of the pancreas or bowel
Folic acid deficiency

Semaglutide

Semaglutide, used for type 2 diabetes mellitus (T2DM) and weight management, shows varied hypoglycemic effects and gastrointestinal reactions. In monotherapy trials for T2DM, severe hypoglycemia was rare but documented symptomatic hypoglycemia occurred in 1.6-3.8% with semaglutide compared to 0% with placebo. Severe hypoglycemia was reported in 1.5% of patients when semaglutide was added to basal insulin, while documented symptomatic hypoglycemia was 16.7-29.8% and severe hypoglycemia was 8.3-10.7%. The risk was higher with sulfonylurea. For semaglutide oral tablets in T2DM monotherapy, severe hypoglycemia was rare, while 6% experienced low blood glucose. Combining semaglutide with insulin led to 1% severe hypoglycemia and 26-32% low blood glucose. Weight loss treatment with semaglutide injection saw clinically significant hypoglycemia in 6.2% of patients.

Gastrointestinal issues were common across semaglutide trials. In monotherapy for T2DM, nausea, vomiting, diarrhea, and abdominal pain occurred. Appendicitis was reported. Weight management trials noted nausea, vomiting, and more at higher doses. Gallbladder events like cholelithiasis and cholecystitis were observed. Renal reactions, including acute renal failure and worsened chronic renal failure, were associated with semaglutide, often linked to gastrointestinal symptoms. Amylase and lipase increases were noted in T2DM trials, with acute pancreatitis reported. Heart rate elevation and hypotension were observed, more in concomitant antihypertensive users. Alopecia affected 3% of weight management patients. Rapid glucose control improvement could exacerbate diabetic retinopathy, particularly in patients with a history of the condition. Semaglutide might relate to thyroid C-cell tumors; regular monitoring of serum calcitonin is recommended.

Hypersensitivity reactions and sinus tachycardia also occurred in some patients. The summarized information underscores the complex range of effects and considerations associated with semaglutide therapy for T2DM and weight management.

Cyanocobalamin

Vitamin B12 is known to be non-toxic even in high doses. The reported adverse reactions following parenteral administration of vitamin B12 include:

Generalized: Anaphylaxis and death
Cardiovascular: Pulmonary edema and congestive cardiac/heart failure during early treatment; peripheral vascular thrombosis
Hematological: Polycythemia vera (a rare type of blood cancer)
Gastrointestinal: Mild, transient diarrhea
Dermatological: Itching; transitory exanthema (widespread skin rash)
Miscellaneous: Feeling of swelling of the entire body

Semaglutide

Cyanocobalamin, a member of the B-complex vitamin family known as cobalamin or corrinoids, is a synthetic form of vitamin B12 found in both prescription and over-the-counter medications. While cyanocobalamin is prevalent in nutritional supplements and fortified foods, it contains a cyano (cyanide) group that enhances its stability compared to other B12 forms, as the cyanide group helps protect the molecule from degradation. Cyanocobalamin is not naturally present in foods due to the presence of cyanide, a constituent absent in the natural B12 form. Compared to other B12 variants, cyanocobalamin is simpler to crystallize and more resistant to air-induced degradation. However, hydroxocobalamin remains the most active B12 form for treating deficiency.

Cyanocobalamin

Cyanocobalamin is contraindicated in those with hypersensitivity to cobalt moiety or cobalamin molecules due to the risk of anaphylaxis.

Warnings:

The use of cyanocobalamin is warned in patients with early Leber’s disease as there have been reports of severe and swift optic atrophy with its administration. Appropriate caution should be exercised while treating severe megaloblastic anemia with cyanocobalamin as intense treatment may lead to hypokalemia and sudden death. Cautious use of parenteral cyanocobalamin is also recommended in patients with renal impairment, including premature neonates, because of the possibility of greater aluminum accumulation, which may cause central nervous system and bone toxicity. Formulations of cyanocobalamin injection containing benzyl alcohol as a preservative should also be avoided in premature neonates and those with hypersensitivity due to its association with ‘gasping syndrome.

Monitoring:

Several laboratory tests should be performed prior to treatment with cyanocobalamin, including serum vitamin B12, folate, iron, hematocrit, and reticulocyte count. For hematocrit and reticulocyte counts, recommendations are to repeat these tests daily from the 5th to 7th days of treatment and then frequently until the hematocrit returns to a normal range. Both serum potassium concentrations and the platelet count need to be monitored carefully after parenteral administration of cyanocobalamin. Therefore, these factors should be taken into consideration and regular monitoring should be performed in these conditions while treating vitamin B12 deficiency with cyanocobalamin.